Guanfacine may help with anxiety, but the evidence is mixed and it is not FDA-approved for any anxiety disorder. It is approved for ADHD in children and adolescents and for high blood pressure in adults. However, its calming effect on the brain’s stress response has led clinicians to prescribe it off-label for anxiety, and early research shows some promise, particularly in younger patients.
How Guanfacine Affects the Brain’s Stress Response
Guanfacine works by stimulating a specific type of receptor in the prefrontal cortex, the part of the brain responsible for planning, impulse control, and emotional regulation. By activating these receptors, it reduces the release of norepinephrine, a chemical messenger that drives the body’s fight-or-flight response. When norepinephrine activity drops in the prefrontal cortex, arousal decreases and the brain’s higher-level control centers gain more influence over reactive, stress-driven pathways.
This is different from how traditional anti-anxiety medications work. SSRIs target serotonin, and benzodiazepines amplify a calming brain chemical called GABA. Guanfacine instead dials down the norepinephrine system, which makes it particularly relevant for people whose anxiety feels more like hyperarousal: racing heart, constant alertness, difficulty winding down, or an exaggerated startle response.
What the Clinical Research Shows
The most direct study on guanfacine for anxiety was a pilot trial published in the Journal of Child and Adolescent Psychopharmacology. Researchers gave extended-release guanfacine (1 to 6 mg daily) or a placebo to 83 children and adolescents aged 6 to 17 with generalized anxiety disorder, separation anxiety disorder, or social anxiety disorder over 12 weeks.
The results were nuanced. On standardized anxiety rating scales filled out by evaluators, children, and parents, both the guanfacine and placebo groups improved, and the differences between them were not statistically significant. Parents of children on guanfacine reported slightly larger drops in anxiety scores than parents of children on placebo, but not enough to be conclusive. However, when clinicians rated overall improvement, 54.2% of children on guanfacine were judged “much improved” or “very much improved,” compared with 31.6% on placebo. That gap suggests a real benefit that the anxiety scales may not have fully captured.
Importantly, guanfacine did not worsen anxiety in any participants, which led the researchers to conclude that clinicians can use it without fear of making anxiety symptoms worse.
Guanfacine for Anxiety With ADHD
Where guanfacine gets the most real-world use for anxiety is in children and adolescents who have both ADHD and anxiety. This combination is common: roughly 30% to 40% of kids with ADHD also have a diagnosable anxiety disorder. Stimulant medications, the first-line treatment for ADHD, can sometimes increase anxiety as a side effect, which puts families and clinicians in a difficult position.
Guanfacine offers an alternative. Studies of children aged 6 to 18 taking extended-release guanfacine for ADHD have found reductions not only in hyperactivity and inattention but also in stress, anxiety, and trauma-related symptoms. A meta-analysis of guanfacine for ADHD found a moderate effect size of 0.51 for oppositional symptoms, and the medication’s calming properties appear to extend to emotional reactivity more broadly. For kids who can’t tolerate stimulants or whose anxiety worsens on them, guanfacine can address both conditions at once.
How It Compares to Clonidine
Clonidine is another medication in the same class that sometimes gets prescribed for anxiety-related symptoms, especially in PTSD. The key difference is selectivity. Guanfacine binds specifically to one receptor subtype, while clonidine binds to multiple subtypes. This makes clonidine more sedating overall, which some clinicians view as a benefit for patients who are extremely agitated or struggling with sleep. Guanfacine tends to produce less sedation at therapeutic doses, which can be preferable when the goal is reducing anxiety without significant drowsiness during the day.
In clinical practice, clonidine is more commonly used for hyperarousal symptoms in PTSD, partly because it has been around longer and is more familiar to prescribers. But guanfacine’s more targeted action may make it a better fit when cognitive clarity matters alongside anxiety relief.
Side Effects to Expect
Sleepiness is the most common side effect by a wide margin. In clinical trials for ADHD, 38% of patients on guanfacine reported somnolence, sedation, or excessive sleepiness, compared to 12% on placebo. This effect is usually strongest in the first few weeks and often fades as the body adjusts, but it caused about 6% of trial participants to stop taking the medication entirely.
Low blood pressure occurred in about 7% of patients (versus 3% on placebo), and some people experience dizziness when standing up quickly. Fatigue, nausea, and lethargy are also reported at rates above placebo. Slowed heart rate is less common, occurring in about 2% of patients taking guanfacine alongside a stimulant.
Because guanfacine lowers blood pressure, combining it with other sedating medications like certain sleep aids, antihistamines, or anti-anxiety drugs can amplify both the blood pressure drop and the drowsiness. The medication is processed in the liver through a specific enzyme pathway (CYP3A4), so certain other medications or even grapefruit juice can raise guanfacine levels in the blood and intensify side effects.
Stopping Guanfacine Safely
Guanfacine should not be stopped abruptly. Because it suppresses norepinephrine activity, sudden withdrawal allows norepinephrine to rebound, which can cause a rise in blood pressure over two to four days. In one study of adults who stopped guanfacine after long-term use, blood pressure climbed gradually, norepinephrine levels exceeded their pre-treatment baseline by day four, and most participants developed headaches starting on the second day. No one in that study experienced a dangerous crisis, likely because guanfacine has a longer duration of action than similar medications, giving the body more time to adjust. Still, the standard approach is to taper the dose down gradually rather than stopping all at once.
The Bottom Line on Guanfacine and Anxiety
Guanfacine is not a proven standalone treatment for anxiety disorders. The one randomized trial focused on pediatric anxiety showed it was safe and well-tolerated, with clinicians rating more patients as improved compared to placebo, but standardized anxiety scales did not show a clear statistical advantage. Its strongest role in managing anxiety is as a secondary benefit in people already taking it for ADHD, especially children and teens whose anxiety coexists with hyperarousal, emotional reactivity, or difficulty tolerating stimulant medications. For adults with anxiety alone, the evidence is largely limited to its use in PTSD-related hyperarousal rather than generalized or social anxiety.